Iomai, Intercell merger on track to close Tuesday

By Lisa Kerner

Charlotte, N.C., Aug. 1 - Iomai Corp. said its stockholders approved the company's merger with a wholly owned subsidiary of Intercell AG.

Approximately 71.6% of Iomai's outstanding shares entitled to vote at the special meeting approved the merger, representing approximately 99.9% of the votes cast, an Iomai news release stated.

The merger is slated to close on or about Aug. 5.

On May 12, Intercell announced it would acquire Iomai for $6.60 a share, or a total of $189 million.

It was previously reported that the Federal Trade Commission granted early termination of the Hart-Scott-Rodino waiting period and the Committee on Foreign Investment in the United States determined there were no unresolved national security concerns in the proposed merger.

Intercell is a biotechnology company based in Vienna.

Iomai is a Gaithersburg, Md., developer of vaccines and immune system stimulants.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.